Improving Life and Reducing Hospital Readmissions in Adults with Acute Hypercapnic Respiratory Failure Using Sleep Studies and High-Flow Nasal Cannula Therapy

What this Trial Is About

This research aims to better understand the role of sleep disorders in patients with acute hypercapnic respiratory failure AHRF, which often leads to frequent unplanned hospital visits and readmissions. The study focuses on patients hospitalized for AHRF, many of whom have additional health issues including untreated sleep problems that may worsen their outcomes. Researchers will investigate sleep abnormalities during hospital stays and two months after discharge, exploring their link to readmission and mortality within one year. Participants will undergo sleep studies using nocturnal EEG and oximetry twice once during a stable phase in the hospital and once at home two months after discharge. A portable device will record sleep data from 500 pm to 800 am. In a smaller group of 21 participants, an additional sleep study will assess how high-flow nasal cannula HFNC therapy, delivered at 25 to 60 liters per minute based on tolerance, affects sleep abnormalities during one night. Throughout the study, researchers will collect information on participants existing health conditions and past hospitalizations. They will monitor clinical outcomes such as hospital readmissions and mortality over one year. Sleep depth and abnormalities will be measured and compared between hospital and home settings. The study will also evaluate the immediate impact of HFNC on sleep quality. Participants will be followed for up to one year to assess these outcomes and the potential benefits of HFNC therapy.

The Simplify Project